M&A Financial Due Diligence

M&A Financial Due Diligence

Overview

Provides a structured framework for financial due diligence in bank M&A transactions, covering earnings quality assessment, balance sheet fair value adjustments, accretion/​dilution analysis, cost and revenue synergy validation, pro-forma capital and liquidity impact, and deal pricing evaluation. Designed for deal committee presentations, board approval packages, and regulatory application support (OCC/​FDIC/​Fed merger applications).

When to Use

• Evaluating a potential bank or financial institution acquisition target
• Building or reviewing accretion/​dilution models for proposed transactions
• Assessing fair value marks on target loan portfolios, securities, and deposits
• Validating cost and revenue synergy assumptions
• Preparing financial analysis sections of regulatory merger applications
• Presenting deal economics to board of directors or deal committee

Required Inputs

Methodology

Step 1 — Assess Target Earnings Quality

Evaluate the sustainability and quality of the target's reported earnings:

NII quality:

• Decompose NIM into asset yield, cost of funds, and free-funds contribution
• Identify non-recurring interest income (accretion from prior deals, penalty income, one-time items)
• Assess the proportion of NII from purchase accounting accretion on prior acquisitions (declining asset)
• Evaluate the loan portfolio yield relative to current origination rates (above-market = roll-off risk)

Fee income quality:

• Separate recurring fees (service charges, wealth management) from volatile income (trading, gain on sale)
• Identify fee income dependent on the rate environment (mortgage banking volumes)
• Assess customer retention risk for fee-generating relationships

Expense normalization:

• Identify one-time costs (restructuring, litigation settlements, deal costs from prior M&A)
• Normalize compensation for above/​below-market levels or unfunded pension obligations
• Assess technology and infrastructure spend: underinvestment creating future catch-up requirements

Core earnings run-rate: Adjusted net income after removing non-recurring items, representing sustainable earnings power.

Step 2 — Mark the Balance Sheet to Fair Value

Estimate fair value adjustments (purchase accounting marks) on major balance sheet categories:

Loan portfolio mark:

• Apply credit mark: Estimate remaining lifetime losses above the existing allowance using loan-level analysis (PD × LGD × EAD) and stress-adjusted scenarios
• Apply rate mark: Discount contractual cash flows at current market rates — below-market fixed-rate loans receive a negative mark, above-market a positive mark
• Segment by loan type (CRE, C&I, resi mortgage, consumer) and apply distinct discount rates and loss assumptions
• Total loan mark = Credit mark + Rate mark (typically a net negative in rising-rate environments)

Securities mark:

• Mark all AFS and HTM securities to current market value
• HTM securities often carry significant unrealized losses in rising-rate environments — these crystallize in a purchase
• Apply haircuts for illiquid or structured securities

Deposit intangible (CDI):

• Core deposit intangible reflects the value of the below-market-rate deposit franchise
• Calculate as: PV of the cost savings from paying deposit rates below wholesale funding rates over the expected life of the deposit base
• Typical valuation: 1-3% of core deposits, amortized over 7-10 years
• Apply deposit decay assumptions based on historical attrition rates

Other fair value adjustments:

• Fixed assets: Appraisal vs. book value
• Trust preferred or subordinated debt: Mark to current market spreads
• Lease obligations: Fair value adjustment for above/​below-market leases
• Contingent liabilities: Legal, regulatory, environmental exposures

Step 3 — Build the Accretion/​Dilution Model

Compute the EPS impact of the transaction on the acquirer:

Key model components:

• Target's contribution: Core earnings run-rate (from Step 1)
• Purchase accounting adjustments: Amortization of loan mark (accretive as discount accretes into income), amortization of CDI (reduces income), amortization of securities mark
• Cost synergies: Phased-in expense reductions (typically 25-35% of target's non-interest expense)
• Revenue synergies: Cross-sell, de novo revenue (apply significant haircut — typically 50% of management estimate)
• Funding cost impact: Any change in the combined entity's funding cost
• Share dilution: Additional shares issued in stock transactions
• Financing cost: Interest expense on debt financing for cash transactions

Accretion/​dilution calculation: Pro-forma EPS = (Acquirer Earnings + Target Core Earnings + Synergies + PA Adjustments − Financing Costs) / Pro-forma Shares A/​D = (Pro-forma EPS − Standalone Acquirer EPS) / Standalone Acquirer EPS

Model over a 5-year horizon showing crossover from dilutive to accretive (if applicable).

Step 4 — Assess Pro-Forma Capital and Liquidity Impact

Evaluate regulatory capital and liquidity impact of the combination:

Capital impact:

• Goodwill creation: Purchase price − Target's fair-value-adjusted net assets = Goodwill
• Goodwill is deducted from CET1 capital (significant negative impact)
• Pro-forma CET1 ratio: (Combined CET1 − Goodwill) / Combined RWA
• Assess whether the combined entity requires a capital raise to maintain target ratios
• Model capital trajectory under internal capital generation assumptions

Liquidity impact:

• Combined LCR and NSFR with pro-forma adjustments
• Assess target's funding profile stability (concentration risk, brokered deposits, FHLB reliance)
• Evaluate incremental borrowing capacity at FHLB and the discount window
• Model pro-forma deposit concentration and diversification benefits

Step 5 — Validate Synergy Assumptions

Critically assess the achievability of projected synergies:

Cost synergies (higher confidence):

• Branch overlap: Map branch networks, identify overlapping markets, estimate closable branches × average branch cost
• Back-office consolidation: Technology platform migration, operations centers, shared services
• Compensation: Eliminate duplicate senior management, overlapping roles
• Vendor rationalization: Consolidate contracts at better pricing
• Apply realistic phase-in: 25% Year 1, 75% Year 2, 100% Year 3
• One-time restructuring costs: Typically 150-200% of annual synergies

Revenue synergies (lower confidence):

• Cross-sell: Target's customer base × acquirer's superior product set × take-up rate
• Apply significant haircut (50-75%) to management revenue synergy estimates
• Revenue synergies typically take 2-3 years to materialize and have high execution risk
• Never model revenue synergies as the primary economic justification for a deal

Step 6 — Evaluate Deal Pricing

Assess whether the price represents fair value:

Valuation multiples:

• Price / Tangible Book Value (P/​TBV): Compare to precedent transactions and trading multiples
• Price / Core Earnings (P/​E): Based on normalized core earnings, not GAAP
• Core deposit premium: (Purchase Price − Target TBV) / Core Deposits
• Premium to market: % above target's current trading price (for public targets)

Breakeven analysis:

• Cost synergies required for break-even accretion (what percentage of target opex must be eliminated?)
• Tangible book value earnback period: Years for acquirer's TBV per share to recover to pre-deal level through retained earnings
• IRR of the investment: Discount rate at which NPV of target's future cash flows equals purchase price

Step 7 — Compile the Due Diligence Assessment

Structure the output as a comprehensive deal assessment:

1. Transaction summary: Price, structure, strategic rationale
2. Earnings quality: Normalized core earnings and sustainability assessment
3. Fair value marks: Balance sheet adjustments with total goodwill estimation
4. Accretion/​dilution: 5-year EPS trajectory with crossover point
5. Capital and liquidity impact: Pro-forma ratios and trajectory
6. Synergy assessment: Validated cost and revenue synergies with confidence levels
7. Pricing evaluation: Multiples comparison and breakeven analysis
8. Key risks: Deal-specific risks and mitigants
9. Recommendation: Proceed / Renegotiate / Decline with supporting rationale

Output Specification

# M&A Financial Due Diligence — [Target Name]

## Transaction Summary
- Purchase price: $[X]M ([Y]x P/​TBV, [Z]x P/​E)
- Consideration: [% cash / % stock]
- Core deposit premium: [X]%
- Strategic rationale: [Brief statement]

## Earnings Quality Assessment
| Metric | Reported | Adjustments | Core Run-Rate |
|--------|----------|-------------|---------------|
| NII | | | |
| Fee Income | | | |
| Expenses | | | |
| Provisions | | | |
| Net Income | | | |

## Fair Value Marks ($M)
| Category | Book Value | Fair Value | Mark | Key Assumptions |
|----------|-----------|-----------|------|-----------------|
| Loan portfolio | | | | |
| Securities | | | | |
| CDI | n/​a | | | |
| Fixed assets | | | | |
| Deposits (premium) | | | | |
| **Net adjustments** | | | **[Total]** | |
| **Goodwill** | | | **[Total]** | |

## Accretion/​Dilution Summary
| | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|------------|--------|--------|--------|--------|--------|
| EPS Impact | | | | | |
| A/​D % | | | | | |

## Pro-Forma Capital & Liquidity
| Metric | Acquirer | Pro-Forma | Target | Impact |
|--------|----------|-----------|--------|--------|
| CET1 | | | ≥[X]% | |
| Leverage | | | ≥[Y]% | |
| LCR | | | ≥100% | |

## Synergy Assessment
| Category | Mgmt Estimate ($M) | Validated ($M) | Confidence | Phase-in |
|----------|--------------------|--------------------|------------|----------|

## Pricing Evaluation
| Multiple | This Deal | Precedent Median | Premium/(Discount) |
|----------|-----------|------------------|--------------------|

TBV Earnback: [X] years | Deal IRR: [Y]%

## Key Risks
1. [Risk with probability and mitigation]

## Recommendation
[Proceed / Renegotiate / Decline with rationale]

Analysis Framework

Apply the Three Tests of Deal Value:

1. Strategic test: Does the target fill a genuine strategic gap (geography, capability, scale)?
2. Financial test: Is the transaction accretive within 2 years with realistic (not aspirational) synergies?
3. Execution test: Can the integration be executed without disrupting either institution's operations or customers?

A deal should pass all three tests before receiving a positive recommendation. Financial attractiveness alone does not justify execution risk.

Examples

Example — Accretion/​Dilution Summary: "At the proposed price of 1.65x TBV ($342M), the transaction is 3.2% dilutive to EPS in Year 1 primarily due to CDI amortization and restructuring charges. With validated cost synergies of $28M (32% of target non-interest expense), the deal crosses to accretive in Q3 of Year 2, reaching 4.8% accretive by Year 3. TBV per share declines from $28.42 to $26.15 at close, with an earnback period of 3.4 years through retained earnings and synergy realization."

Example — Fair Value Mark Narrative: "The loan portfolio carries a net negative mark of $67M (3.8% of book value), comprising a $42M credit mark reflecting estimated additional lifetime losses in the CRE portfolio above existing reserves, and a $25M rate mark on $480M of fixed-rate residential mortgages originated at 3.25% average coupon. The credit mark is driven by 12 classified CRE relationships totaling $184M with updated appraisals showing LTVs of 85-110%. The rate mark accretes into income over the portfolio's 6.2-year weighted average life."

Guidelines

• Always normalize target earnings before applying valuation multiples
• Apply independent credit judgment on the loan portfolio — do not rely solely on target's internal grades
• Model accretion/​dilution over 5 years, not just Year 1
• Haircut revenue synergies by at least 50% from management estimates
• Include one-time restructuring costs in accretion/​dilution (not just run-rate synergies)
• Assess pro-forma capital impact including full goodwill deduction from CET1
• Compare deal pricing to both precedent transactions and current trading multiples
• Never justify a deal primarily on revenue synergies — cost synergies must independently support the price

Validation Checklist

• Target earnings normalized for non-recurring items with clear adjustments documented
• Loan portfolio mark reflects both credit and rate components
• CDI valuation uses appropriate deposit decay and discount rate assumptions
• Goodwill calculated as purchase price minus fair-value-adjusted net assets
• Accretion/​dilution model includes PA amortization, synergies, restructuring, and financing costs
• Pro-forma CET1 ratio computed with full goodwill deduction
• Cost synergies benchmarked against comparable transactions (25-35% of target OpEx)
• Revenue synergies haircut by ≥50% from management estimates
• Deal multiples compared to precedent transactions and current trading multiples
• TBV earnback period and deal IRR calculated and assessed against thresholds